BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26356635)

  • 1. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.
    Fazeli SR; Zehr B; Amraei R; Toraldo G; Guan H; Kindelberger D; Lee S; Cerda S
    Thyroid; 2020 Oct; 30(10):1528-1534. PubMed ID: 32349630
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
    O'Conor CJ; Dash RC; Jones CK; Jiang XS
    Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign call rate and molecular test result distribution of ThyroSeq v3.
    Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
    Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
    Na DG; Kim JH; Sung JY; Baek JH; Jung KC; Lee H; Yoo H
    Thyroid; 2012 May; 22(5):468-75. PubMed ID: 22304417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid fine-needle aspirations: A six-year institutional experience.
    Xu XM; Angelova E; Clement CG
    Diagn Cytopathol; 2021 Aug; 49(8):915-920. PubMed ID: 33973739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
    Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
    Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Lymphocytic Thyroiditis May Limit the Utility of Molecular Testing in AUS/FLUS Thyroid Nodules.
    Remer LF; Linhares SM; Scola WH; Lew JI
    J Surg Res; 2023 Sep; 289():229-233. PubMed ID: 37148856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
    Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
    Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of repeat fine-needle aspiration in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: A single center experience.
    Marin F; Murillo R; Diego C; Jodar E; Acevedo A
    Diagn Cytopathol; 2021 Mar; 49(3):412-417. PubMed ID: 33252841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
    Nikiforov YE; Ohori NP; Hodak SP; Carty SE; LeBeau SO; Ferris RL; Yip L; Seethala RR; Tublin ME; Stang MT; Coyne C; Johnson JT; Stewart AF; Nikiforova MN
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3390-7. PubMed ID: 21880806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.